CA2383293C - Anti-infective compositions for treating disordered tissue such as cold sores - Google Patents
Anti-infective compositions for treating disordered tissue such as cold sores Download PDFInfo
- Publication number
- CA2383293C CA2383293C CA2383293A CA2383293A CA2383293C CA 2383293 C CA2383293 C CA 2383293C CA 2383293 A CA2383293 A CA 2383293A CA 2383293 A CA2383293 A CA 2383293A CA 2383293 C CA2383293 C CA 2383293C
- Authority
- CA
- Canada
- Prior art keywords
- treatment composition
- recited
- disordered tissue
- tissue
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 431
- 208000004898 Herpes Labialis Diseases 0.000 title claims abstract description 90
- 230000002924 anti-infective effect Effects 0.000 title claims abstract description 38
- 206010067152 Oral herpes Diseases 0.000 title abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 334
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 46
- 150000008282 halocarbons Chemical group 0.000 claims abstract description 24
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims abstract description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 108
- 238000013019 agitation Methods 0.000 claims description 102
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 239000000835 fiber Substances 0.000 claims description 40
- 235000019441 ethanol Nutrition 0.000 claims description 33
- 230000035515 penetration Effects 0.000 claims description 30
- 239000003921 oil Substances 0.000 claims description 28
- 208000026062 Tissue disease Diseases 0.000 claims description 21
- 241000700584 Simplexvirus Species 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 230000003444 anaesthetic effect Effects 0.000 claims description 14
- 150000004045 organic chlorine compounds Chemical class 0.000 claims description 14
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 13
- -1 benzalkonium bromide compound Chemical class 0.000 claims description 13
- 208000007514 Herpes zoster Diseases 0.000 claims description 12
- 229960004150 aciclovir Drugs 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000002777 nucleoside Substances 0.000 claims description 12
- 230000000149 penetrating effect Effects 0.000 claims description 12
- 208000003589 Spider Bites Diseases 0.000 claims description 11
- 208000025865 Ulcer Diseases 0.000 claims description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 11
- 239000004599 antimicrobial Substances 0.000 claims description 11
- 206010003399 Arthropod bite Diseases 0.000 claims description 10
- 229960005475 antiinfective agent Drugs 0.000 claims description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 231100000397 ulcer Toxicity 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 229960001950 benzethonium chloride Drugs 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 229920002994 synthetic fiber Polymers 0.000 claims description 8
- 239000012209 synthetic fiber Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 6
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 6
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 6
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 6
- 229960005443 chloroxylenol Drugs 0.000 claims description 6
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 6
- 229960004068 hexachlorophene Drugs 0.000 claims description 6
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 229960003500 triclosan Drugs 0.000 claims description 6
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 229960000541 cetyl alcohol Drugs 0.000 claims description 5
- 229960003260 chlorhexidine Drugs 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- JMHWNJGXUIJPKG-UHFFFAOYSA-N CC(=O)O[SiH](CC=C)OC(C)=O Chemical compound CC(=O)O[SiH](CC=C)OC(C)=O JMHWNJGXUIJPKG-UHFFFAOYSA-N 0.000 claims description 4
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- RCTOVWPTGOZSPJ-UHFFFAOYSA-N benzyl(ethyl)azanium;chloride Chemical compound Cl.CCNCC1=CC=CC=C1 RCTOVWPTGOZSPJ-UHFFFAOYSA-N 0.000 claims description 3
- SCXCDVTWABNWLW-UHFFFAOYSA-M decyl-dimethyl-octylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCC SCXCDVTWABNWLW-UHFFFAOYSA-M 0.000 claims description 3
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 claims description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 9
- 239000007864 aqueous solution Substances 0.000 claims 6
- 230000006835 compression Effects 0.000 claims 4
- 238000007906 compression Methods 0.000 claims 4
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 claims 4
- 239000011800 void material Substances 0.000 claims 3
- CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000013530 defoamer Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 59
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 210000000981 epithelium Anatomy 0.000 abstract description 11
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 259
- 206010001497 Agitation Diseases 0.000 description 78
- 238000000034 method Methods 0.000 description 58
- 239000000126 substance Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 24
- 241000219307 Atriplex rosea Species 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 22
- 230000036407 pain Effects 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 22
- 230000007794 irritation Effects 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 206010037844 rash Diseases 0.000 description 19
- 210000003979 eosinophil Anatomy 0.000 description 16
- 239000000853 adhesive Substances 0.000 description 15
- 230000001070 adhesive effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 229920000742 Cotton Polymers 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 210000001508 eye Anatomy 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 206010039509 Scab Diseases 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 239000003082 abrasive agent Substances 0.000 description 8
- 210000001640 nerve ending Anatomy 0.000 description 8
- 230000035807 sensation Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 239000002250 absorbent Substances 0.000 description 6
- 230000002745 absorbent Effects 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000004264 Petrolatum Substances 0.000 description 5
- 229940035674 anesthetics Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 208000035824 paresthesia Diseases 0.000 description 5
- 229940066842 petrolatum Drugs 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000723346 Cinnamomum camphora Species 0.000 description 4
- 208000031973 Conjunctivitis infective Diseases 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000437 stratum spinosum Anatomy 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010019973 Herpes virus infection Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000005844 Thymol Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229960005274 benzocaine Drugs 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 229960005233 cineole Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229960000790 thymol Drugs 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 2
- 239000001074 1-methoxy-4-[(E)-prop-1-enyl]benzene Substances 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000238865 Loxosceles reclusa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010037898 Rash vesicular Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960004867 hexetidine Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000012784 inorganic fiber Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 210000000439 stratum lucidum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 1
- UFWWXJRCWHOHOQ-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)propyl 4-cyclohexyloxybenzoate;hydrochloride Chemical compound Cl.CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 UFWWXJRCWHOHOQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000238866 Latrodectus mactans Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 240000000907 Musa textilis Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 235000005018 Pinus echinata Nutrition 0.000 description 1
- 241001236219 Pinus echinata Species 0.000 description 1
- 235000017339 Pinus palustris Nutrition 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940057188 blistex Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- ATAGSVCDFKGYPE-UHFFFAOYSA-N butamben picrate Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1.CCCCOC(=O)C1=CC=C(N)C=C1.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ATAGSVCDFKGYPE-UHFFFAOYSA-N 0.000 description 1
- 229960004008 butamben picrate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940105270 carbocaine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
- 229960004741 cyclomethycaine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960002228 diperodon Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 description 1
- 229960003462 dyclonine hydrochloride Drugs 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940066760 new-skin liquid bandage Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000037325 pain tolerance Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
- A61M35/006—Portable hand-held applicators having means for dispensing or spreading integral media using sponges, foams, absorbent pads or swabs as spreading means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/401,076 US6211243B1 (en) | 1999-09-22 | 1999-09-22 | Methods for treating cold sores with anti-infective compositions |
| US09/401,076 | 1999-09-22 | ||
| PCT/US2000/026198 WO2001020981A2 (en) | 1999-09-22 | 2000-09-22 | Anti-infective compositions for treating disordered tissue such as cold sores |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2383293A1 CA2383293A1 (en) | 2001-03-29 |
| CA2383293C true CA2383293C (en) | 2010-11-02 |
Family
ID=23586190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002384829A Abandoned CA2384829A1 (en) | 1999-09-22 | 2000-09-22 | Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| CA2383293A Expired - Lifetime CA2383293C (en) | 1999-09-22 | 2000-09-22 | Anti-infective compositions for treating disordered tissue such as cold sores |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002384829A Abandoned CA2384829A1 (en) | 1999-09-22 | 2000-09-22 | Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US6211243B1 (enExample) |
| EP (2) | EP1404174B1 (enExample) |
| JP (2) | JP5215514B2 (enExample) |
| AR (1) | AR025763A1 (enExample) |
| AT (2) | ATE491436T1 (enExample) |
| AU (3) | AU777656B2 (enExample) |
| BR (2) | BR0014205B1 (enExample) |
| CA (2) | CA2384829A1 (enExample) |
| DE (3) | DE60045394D1 (enExample) |
| GB (2) | GB2370773B (enExample) |
| MX (2) | MXPA02002975A (enExample) |
| PE (1) | PE20010709A1 (enExample) |
| WO (3) | WO2001020981A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846919B2 (en) * | 1998-02-10 | 2010-12-07 | Dermex Pharmaceuticals, Llc | Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
| US6224579B1 (en) * | 1999-03-31 | 2001-05-01 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
| US6641591B1 (en) | 1999-08-26 | 2003-11-04 | John H. Shadduck | Instruments and techniques for controlled removal of epidermal layers |
| US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
| US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
| US6211243B1 (en) * | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
| US6835184B1 (en) * | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
| US7329412B2 (en) * | 2000-12-22 | 2008-02-12 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices containing chlorhexidine free base and salt |
| US6846846B2 (en) * | 2001-10-23 | 2005-01-25 | The Trustees Of Columbia University In The City Of New York | Gentle-acting skin disinfectants |
| US20030143264A1 (en) * | 2002-01-30 | 2003-07-31 | Vincent Margiotta | Topical anesthetic-antiseptic patch |
| EP1480517A4 (en) * | 2002-02-07 | 2007-08-22 | Univ Columbia | ZINC SALT COMPOSITIONS FOR PREVENTING MOLECULAR BREAST EXTRACTION THROUGH SPERMICIDES AND MICROBICIDES |
| US7879365B2 (en) * | 2002-02-07 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
| US7745425B2 (en) * | 2002-02-07 | 2010-06-29 | The Trustees Of Columbia University In The City Of New York | Non-irritating compositions containing zinc salts |
| US20030224474A1 (en) * | 2002-05-30 | 2003-12-04 | Litman Mark A. | Rapid-acting drug analysis system |
| US7261701B2 (en) * | 2002-10-03 | 2007-08-28 | 3M Innovative Properties Co. | Skin antiseptic composition dispenser and methods of use |
| US8105306B2 (en) * | 2002-10-03 | 2012-01-31 | 3M Innovative Properties Company | Skin antiseptic composition dispenser and methods of use |
| US20040204489A1 (en) * | 2003-04-14 | 2004-10-14 | Arthur Vanmoor | Method of treating a swollen gland curing cancer |
| US20040208908A1 (en) * | 2003-04-16 | 2004-10-21 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical articles containing a synergistic combination of anti-infective compounds and octoxyglycerin |
| JP2007534620A (ja) * | 2003-07-17 | 2007-11-29 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 第４級アンモニウム化合物と精油および／またはその構成要素の相乗的組合せを含む抗菌組成物 |
| US20050019422A1 (en) * | 2003-07-23 | 2005-01-27 | Allergan, Inc. | Method and composition for treating acne |
| CN1867251A (zh) * | 2003-09-09 | 2006-11-22 | 3M创新有限公司 | 抗菌组合物和方法 |
| CA2538119C (en) * | 2003-09-09 | 2013-05-14 | 3M Innovative Properties Company | Concentrated antimicrobial compositions and methods |
| US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| MXPA06002917A (es) * | 2003-09-15 | 2006-05-31 | Schering Corp | Sintesis de quinolina 5-carboxamidas utiles para la preparacion de inhibidores de fosfodiesterasa iv. |
| US20070218115A1 (en) * | 2003-10-27 | 2007-09-20 | Bott Richard R | Preparation for Topical Application and Methods of Delivering an Active Agent to a Substrate |
| CA2543940A1 (en) * | 2003-10-27 | 2005-05-19 | Dow Corning Corporation | Preparations for topical application and methods of delivering an active agent to a substrate |
| US20050100601A1 (en) * | 2003-11-07 | 2005-05-12 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
| US20090232748A1 (en) * | 2003-11-07 | 2009-09-17 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
| US20050154343A1 (en) * | 2004-01-14 | 2005-07-14 | Mohinder Singh | Soft tip applicator for relieving mouth pain |
| US7316665B2 (en) * | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
| US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| US20060121098A1 (en) * | 2004-11-15 | 2006-06-08 | Mendoza Randall P | Dermal defense system and method of use |
| US20050111900A1 (en) * | 2004-11-30 | 2005-05-26 | Francesca Fazzolari | Ampoule and method of use |
| US20060173514A1 (en) * | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
| US8529560B2 (en) | 2005-03-04 | 2013-09-10 | The Invention Science Fund I, Llc | Hair treatment system |
| US8540701B2 (en) * | 2005-03-04 | 2013-09-24 | The Invention Science Fund I, Llc | Hair treatment system |
| US20060200114A1 (en) * | 2005-03-04 | 2006-09-07 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Hair removal system with light source array |
| US8679101B2 (en) * | 2005-03-04 | 2014-03-25 | The Invention Science Fund I, Llc | Method and system for temporary hair removal |
| US20060276859A1 (en) * | 2005-06-02 | 2006-12-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Photopatterning of skin |
| US8157807B2 (en) | 2005-06-02 | 2012-04-17 | The Invention Science Fund I, Llc | Skin treatment including patterned light |
| US8476319B2 (en) * | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
| BRPI0608691A2 (pt) * | 2005-03-10 | 2010-12-07 | 3M Innovative Properties Company | composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição |
| US20060229364A1 (en) * | 2005-03-10 | 2006-10-12 | 3M Innovative Properties Company | Antiviral compositions and methods of use |
| EP1868686A2 (en) * | 2005-03-10 | 2007-12-26 | 3M Innovative Properties Company | Antimicrobial pet wipes |
| CA2599653A1 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| US20070032846A1 (en) * | 2005-08-05 | 2007-02-08 | Bran Ferren | Holographic tattoo |
| US9055958B2 (en) * | 2005-06-29 | 2015-06-16 | The Invention Science Fund I, Llc | Hair modification using converging light |
| US20070038270A1 (en) * | 2005-07-05 | 2007-02-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step photopatterning of skin |
| US20070048340A1 (en) * | 2005-08-31 | 2007-03-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step patterning of a skin surface |
| US20070166402A1 (en) * | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
| US20070147946A1 (en) * | 2005-12-23 | 2007-06-28 | 3M Innovative Properties Cornpany | Surgical prep solution applicator |
| US8048089B2 (en) | 2005-12-30 | 2011-11-01 | Edge Systems Corporation | Apparatus and methods for treating the skin |
| US7759327B2 (en) * | 2006-01-06 | 2010-07-20 | The Trustees Of Columbia University In The City Of New York | Compositions containing zinc salts for coating medical articles |
| US10172644B2 (en) | 2006-03-29 | 2019-01-08 | Edge Systems Llc | Devices, systems and methods for treating the skin |
| US9566088B2 (en) | 2006-03-29 | 2017-02-14 | Edge Systems Llc | Devices, systems and methods for treating the skin |
| US7662177B2 (en) | 2006-04-12 | 2010-02-16 | Bacoustics, Llc | Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy |
| US20080075793A1 (en) * | 2006-09-21 | 2008-03-27 | Dunshee Wayne K | Antiviral compositions and methods of use |
| US7785026B2 (en) | 2007-01-08 | 2010-08-31 | Serena Eng | Cosmetic applicator device |
| US8741954B2 (en) * | 2007-02-21 | 2014-06-03 | Viratox, L.L.C. | Synergistic enhancement of calcium propionate |
| US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
| EP2240031B1 (en) * | 2007-12-31 | 2013-09-18 | 3M Innovative Properties Company | Antimicrobial compositions |
| JP5508285B2 (ja) | 2008-01-04 | 2014-05-28 | エッジ システムズ コーポレーション | 皮膚を治療するための装置および方法 |
| US8814836B2 (en) | 2008-01-29 | 2014-08-26 | Edge Systems Llc | Devices, systems and methods for treating the skin using time-release substances |
| WO2009097451A1 (en) | 2008-01-29 | 2009-08-06 | Edge Systems Corporation | Apparatus and method for treating the skin |
| RU2519385C2 (ru) * | 2008-05-26 | 2014-06-10 | Новартис Аг | Набор для местного нанесения лекарственных средств |
| KR100950004B1 (ko) * | 2008-07-10 | 2010-03-31 | 수 경 최 | 구강염 치료용 스틱 |
| US20100086625A1 (en) * | 2008-10-08 | 2010-04-08 | Abukurah Abdul R | Methods for treating skin lesions |
| US20100094249A1 (en) * | 2008-10-09 | 2010-04-15 | Ty Caswell | Wound treatment apparatus and methods |
| US20100316716A1 (en) * | 2009-06-11 | 2010-12-16 | Abukurah Abdul R | Method for treating herpes zoster lesions |
| EP2263796B1 (de) * | 2009-06-20 | 2018-07-25 | Roche Diabetes Care GmbH | Behälter mit Referenzlösung |
| US20110045103A1 (en) * | 2009-08-19 | 2011-02-24 | Abukurah Abdul R | Methods for treating aids |
| WO2011057363A1 (en) * | 2009-11-16 | 2011-05-19 | Dynamiclear Pty Ltd | Disposable device and uses thereof for skin and mucosal applications |
| US8846725B2 (en) | 2011-01-24 | 2014-09-30 | Quadex Pharmaceuticals, Llc | Highly penetrating compositions and methods for treating pathogen-induced disordered tissues |
| US20120225143A1 (en) * | 2011-03-03 | 2012-09-06 | Ranir, Llc | Cold sore formulation and related method of manufacture |
| WO2012152612A1 (en) * | 2011-05-06 | 2012-11-15 | Bayer Consumer Care Ag | Stick pack with applicator |
| JP6609183B2 (ja) * | 2012-09-19 | 2019-11-20 | イノベイティブ ファーマシューティカル コンセプツ（アイピーシー）インコーポレイテッド | 医療用塗布器 |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9125911B2 (en) * | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US10238812B2 (en) | 2013-03-15 | 2019-03-26 | Edge Systems Llc | Skin treatment systems and methods using needles |
| ES2936988T3 (es) | 2013-03-15 | 2023-03-23 | Hydrafacial Llc | Dispositivos y sistemas para el tratamiento de la piel |
| US10183039B2 (en) | 2013-07-15 | 2019-01-22 | Vanderbilt University | Methods for the production of collagen IV |
| EP3237021B1 (en) * | 2014-12-22 | 2020-12-23 | Flexible Medical Packaging Ltd. | Sanitising device |
| EP3237055B1 (en) | 2014-12-23 | 2020-08-12 | Edge Systems LLC | Devices and methods for treating the skin using a rollerball or a wicking member |
| US10179229B2 (en) | 2014-12-23 | 2019-01-15 | Edge Systems Llc | Devices and methods for treating the skin using a porous member |
| EP4197517A1 (en) | 2015-07-08 | 2023-06-21 | HydraFacial LLC | Devices, systems and methods for promoting hair growth |
| CN105494343A (zh) * | 2015-12-21 | 2016-04-20 | 常州市精尔锐工具制造有限公司 | 一种新型杀菌剂组合物 |
| EP3755368A4 (en) | 2018-02-23 | 2021-12-22 | The Administrators of The Tulane Educational Fund | PHARMACEUTICAL COMPOSITION FOR VIRUS INFECTIONS |
| US10369396B1 (en) * | 2018-11-09 | 2019-08-06 | Battelle Memorial Institute | Assembly for decontaminating and method of manufacturing the assembly |
| US20220079319A1 (en) * | 2018-12-19 | 2022-03-17 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Variable dose applicator |
| US11919672B2 (en) | 2019-04-12 | 2024-03-05 | Avery Dennison Corporation | Apparatus and methods for fastening an element to a support structure |
| USD935875S1 (en) | 2019-11-25 | 2021-11-16 | Avery Dennison Corporation | Fastener |
| USD936467S1 (en) | 2019-11-25 | 2021-11-23 | Avery Dennison Corporation | Fastener set |
| US11291474B2 (en) | 2020-01-06 | 2022-04-05 | Ed F. Nicolas | Skin treatment tool applicator tip |
| USD1016615S1 (en) | 2021-09-10 | 2024-03-05 | Hydrafacial Llc | Container for a skin treatment device |
| USD1065551S1 (en) | 2021-09-10 | 2025-03-04 | Hydrafacial Llc | Skin treatment device |
| USD1042807S1 (en) | 2021-10-11 | 2024-09-17 | Hydrafacial Llc | Skin treatment tip |
| USD1084369S1 (en) | 2023-02-10 | 2025-07-15 | Hydrafacial Llc | Skin treatment tip |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1519693A (en) | 1924-03-05 | 1924-12-16 | Fred R Moore | Rotary medicine applicator |
| US1822566A (en) | 1928-11-02 | 1931-09-08 | Mine Safety Appliances Co | Medicament applicator |
| US3369543A (en) | 1965-03-30 | 1968-02-20 | Deron Inc | Medicinal applicators |
| US3614245A (en) | 1967-08-15 | 1971-10-19 | Gilbert Schwartzman | Single-use applicator |
| JPS5038393A (enExample) | 1973-08-10 | 1975-04-09 | ||
| US4183684A (en) | 1977-11-29 | 1980-01-15 | Marion Health & Safety, Inc. | Fluid dispensing unit |
| US4176197A (en) * | 1978-02-03 | 1979-11-27 | Dominion Pharmacal, Inc. | Method for treating acne vulgaris |
| US4390539A (en) * | 1979-04-13 | 1983-06-28 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the treatment of viral skin diseases |
| US4262007A (en) * | 1979-04-13 | 1981-04-14 | George F. Sherrill | Method for the treatment of viral skin diseases |
| US4394381A (en) | 1979-04-13 | 1983-07-19 | George F. And Irene Sherrill 1978 Trust No. 1 | Method for the relief of pain |
| US4486450B1 (en) | 1980-07-14 | 1998-07-28 | Joel E Bernstein | Method of treating psoriatic skin and composition |
| US4975217A (en) | 1981-07-20 | 1990-12-04 | Kimberly-Clark Corporation | Virucidal composition, the method of use and the product therefor |
| US4507281A (en) | 1981-10-13 | 1985-03-26 | Exovir, Inc. | Interferon-containing compositions |
| US4957734A (en) | 1982-06-14 | 1990-09-18 | Exovir, Inc. | Treatment of certain skin malignancies and pre-malignant skin lesions, herpes zoster and psoriasis |
| US4661354A (en) | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
| US4797420A (en) * | 1984-08-14 | 1989-01-10 | Jabco Manufacturing, Inc. | Disinfectant formulation and method of use |
| JPS6176401A (ja) * | 1984-09-19 | 1986-04-18 | Takeda Chem Ind Ltd | 殺菌消毒剤および殺菌消毒法 |
| EP0175338A3 (en) | 1984-09-19 | 1988-06-01 | Takeda Chemical Industries, Ltd. | Disinfectants and antiseptics |
| GB8427770D0 (en) | 1984-11-02 | 1984-12-12 | Bio Medical Services Ltd | Applying drug solution |
| US4828542A (en) | 1986-08-29 | 1989-05-09 | Twin Rivers Engineering | Foam substrate and micropackaged active ingredient particle composite dispensing materials |
| EP0190797A3 (en) | 1985-02-08 | 1987-05-20 | John Kenneth Voit | Method for killing viruses and composition therefor |
| US4895727A (en) | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
| US4822605A (en) | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| US5458889A (en) | 1986-05-22 | 1995-10-17 | Atlantic Pharmaceutical Products Limited | Methods and compositions for inhibiting or destroying viruses or retroviruses |
| US4929442A (en) | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| JPS6388861U (enExample) * | 1986-11-27 | 1988-06-09 | ||
| US5712257A (en) | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| CA1273576A (en) | 1987-09-16 | 1990-09-04 | Patrick A. Beauchamp | Topical treatment for diseased skin disorders |
| US4875602A (en) | 1988-06-15 | 1989-10-24 | Triad Direct Incorporated | Self-contained liquid dispensing device |
| US4887994A (en) | 1988-07-06 | 1989-12-19 | Bedford Peter H | Applicator swabs and method of making same |
| NO178843C (no) | 1988-07-11 | 1996-06-19 | Sspl Sa Safe Sex Prod Licens | Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer |
| US4952204A (en) * | 1988-08-10 | 1990-08-28 | Gam-Med Packaging Corporation | Dry handle swab assembly and unit |
| US5405602A (en) | 1989-01-31 | 1995-04-11 | Simmons; Paul L. | Nonaqueous cold sterilant |
| US5637307A (en) | 1989-01-31 | 1997-06-10 | Simmons; Paul L. | Method of immersion sterilization and organic cold chemical sterilant |
| US5016651A (en) | 1989-08-29 | 1991-05-21 | Stalcup Robert W | Method of providing topoical anesthetic in a sanitary and convenient manner |
| US5036095A (en) | 1989-11-14 | 1991-07-30 | Guy Andermann | Therapeutic use of DMDM Hydantoin |
| US5137724A (en) | 1990-05-23 | 1992-08-11 | Stichting Rega Vzw | Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines |
| GB9015910D0 (en) | 1990-07-19 | 1990-09-05 | Univ Bruxelles | Novel use |
| US6355684B1 (en) | 1990-10-11 | 2002-03-12 | Meryl J. Squires | Antimicrobial treatment for herpes simplex virus and other infectious diseases |
| JP3055796B2 (ja) * | 1990-11-19 | 2000-06-26 | 善蔵 田村 | 殺菌消毒剤組成物 |
| US5198217A (en) | 1991-09-24 | 1993-03-30 | Choice Pharmaceuticals | Topical demulcent for viral and inflammatory diseases of the skin |
| US6350784B1 (en) | 1996-02-12 | 2002-02-26 | Meryl J. Squires | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| US5229423A (en) | 1992-03-06 | 1993-07-20 | Albert Einstein College Of Medicine Of Yeshiva University | Use of butylurea as a contraceptive agent |
| AU5541594A (en) | 1992-10-21 | 1994-05-09 | Gynetech Laboratories, Inc. | Vaginal sponge delivery system |
| FR2700698A1 (fr) | 1992-11-09 | 1994-07-29 | Mercurochrome Lab | Unité de distribution de fluides particulièrement sensibles à la lumière, et/ou à la contamination bactérienne. |
| US5370876A (en) | 1993-01-08 | 1994-12-06 | Microbarriers | Antimicrobial protective skin composition and method for protecting skin from body fluids |
| US5767163A (en) | 1994-02-22 | 1998-06-16 | Kundsin Leduc Lenmark Inc. | Lubricating and/or germicidal composition |
| US5492932A (en) * | 1994-02-22 | 1996-02-20 | Kundsin Leduc Lenmark, Inc. | Lubrication germicidal composition |
| US5661170A (en) | 1994-03-21 | 1997-08-26 | Woodward Laboratories, Inc. | Antimicrobial compositions and methods for using the same |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| JPH08164191A (ja) * | 1994-12-13 | 1996-06-25 | Kankyo Planning:Kk | 消毒・除菌用ウエットティッシュ |
| JPH08217694A (ja) * | 1995-02-09 | 1996-08-27 | Pola Chem Ind Inc | 抗掻痒皮膚外用剤 |
| CA2143136A1 (en) | 1995-02-22 | 1996-08-23 | Chris Morris | Rub on topical anesthetic |
| US5631245A (en) | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
| US5906814A (en) | 1995-12-07 | 1999-05-25 | The Andrew Jergens Company | Topical film-forming compositions |
| US5704906A (en) | 1996-02-26 | 1998-01-06 | Fox; Richard L. | Method of using a topical anesthetic-cleaning solution and applicator |
| US5678273A (en) | 1996-03-20 | 1997-10-21 | Porcelli; V. Lorenzo | Disposable oral hygiene applicator |
| US5952392A (en) | 1996-09-17 | 1999-09-14 | Avanir Pharmaceuticals | Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition |
| US5709866A (en) | 1996-12-05 | 1998-01-20 | Sage Products, Inc. | Dual bag mouth care package |
| US5948822A (en) | 1996-12-17 | 1999-09-07 | Lidak Pharmaceuticals | Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols |
| JPH10324624A (ja) * | 1997-05-23 | 1998-12-08 | Kao Corp | 殺菌消毒剤組成物 |
| DE69840524D1 (de) | 1997-08-13 | 2009-03-19 | Uab Research Foundation | Impfung durch topische verwendung genetischer vektoren |
| GB9718791D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Medicaments |
| EP1023899A1 (en) * | 1997-09-26 | 2000-08-02 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation containing antiviral agent having purine or pyrimidine skeleton |
| US6211243B1 (en) * | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
-
1999
- 1999-09-22 US US09/401,076 patent/US6211243B1/en not_active Expired - Lifetime
-
2000
- 2000-09-22 GB GB0207537A patent/GB2370773B/en not_active Expired - Fee Related
- 2000-09-22 MX MXPA02002975A patent/MXPA02002975A/es active IP Right Grant
- 2000-09-22 AT AT00965383T patent/ATE491436T1/de not_active IP Right Cessation
- 2000-09-22 CA CA002384829A patent/CA2384829A1/en not_active Abandoned
- 2000-09-22 AU AU76108/00A patent/AU777656B2/en not_active Ceased
- 2000-09-22 DE DE60045394T patent/DE60045394D1/de not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026198 patent/WO2001020981A2/en not_active Ceased
- 2000-09-22 AT AT00965399T patent/ATE492268T1/de not_active IP Right Cessation
- 2000-09-22 BR BRPI0014205-0A patent/BR0014205B1/pt not_active IP Right Cessation
- 2000-09-22 GB GB0207539A patent/GB2370774B/en not_active Expired - Fee Related
- 2000-09-22 WO PCT/US2000/025994 patent/WO2001021170A1/en not_active Ceased
- 2000-09-22 WO PCT/US2000/026284 patent/WO2001021171A1/en not_active Ceased
- 2000-09-22 US US09/668,951 patent/US6414032B1/en not_active Expired - Lifetime
- 2000-09-22 JP JP2001524422A patent/JP5215514B2/ja not_active Expired - Fee Related
- 2000-09-22 US US09/669,068 patent/US6420431B1/en not_active Expired - Lifetime
- 2000-09-22 JP JP2001524597A patent/JP5041643B2/ja not_active Expired - Fee Related
- 2000-09-22 BR BR0014209-3A patent/BR0014209A/pt active Search and Examination
- 2000-09-22 CA CA2383293A patent/CA2383293C/en not_active Expired - Lifetime
- 2000-09-22 DE DE60045418T patent/DE60045418D1/de not_active Expired - Lifetime
- 2000-09-22 US US09/668,953 patent/US6423750B1/en not_active Expired - Lifetime
- 2000-09-22 PE PE2000001001A patent/PE20010709A1/es not_active Application Discontinuation
- 2000-09-22 EP EP00965383A patent/EP1404174B1/en not_active Expired - Lifetime
- 2000-09-22 DE DE10085007T patent/DE10085007T1/de not_active Withdrawn
- 2000-09-22 MX MXPA02002974A patent/MXPA02002974A/es active IP Right Grant
- 2000-09-22 AU AU76030/00A patent/AU7603000A/en not_active Abandoned
- 2000-09-22 AU AU76124/00A patent/AU771816B2/en not_active Ceased
- 2000-09-22 EP EP00965399A patent/EP1214064B1/en not_active Expired - Lifetime
- 2000-09-22 AR ARP000105002A patent/AR025763A1/es not_active Application Discontinuation
-
2001
- 2001-11-06 US US09/993,178 patent/US6410599B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2383293C (en) | Anti-infective compositions for treating disordered tissue such as cold sores | |
| US8217080B2 (en) | Anti-infective methods and systems for treating pathogen-induced disordered tissues | |
| US6759434B2 (en) | Anti-infective compositions, methods and systems for treating disordered tissue | |
| US9314526B2 (en) | Highly penetrating compositions with benzocaine for treating disordered tissues | |
| US9463180B2 (en) | Treatment of molluscum contagiosum | |
| AU2012209412A1 (en) | Highly penetrating compositions and methods for treating pathogen-induced disordered tissues | |
| AU2004202929B2 (en) | Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores | |
| NZ613262B2 (en) | Highly penetrating compositions and methods for treating pathogen-induced disordered tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20200922 |